{"protocolSection":{"identificationModule":{"nctId":"NCT06480565","orgStudyIdInfo":{"id":"ADI-202427001"},"organization":{"fullName":"Adicet Therapeutics","class":"INDUSTRY"},"briefTitle":"A Phase 1/2 Trial of ADI-270 in ccRCC","officialTitle":"A Phase 1/2 Trial of ADI-270 (Engineered γδ Chimeric Receptor [CAR] Vδ1 T Cells Targeting CD70) in Adults With Relapsed or Refractory (R/R) Clear Cell Renal Cell Carcinoma (ccRCC)"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-09","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2025-06","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-06","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-25","studyFirstSubmitQcDate":"2024-06-25","studyFirstPostDateStruct":{"date":"2024-06-28","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-25","lastUpdatePostDateStruct":{"date":"2024-06-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Adicet Therapeutics","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a Phase 1/2 multicenter, open-label, dose escalation, and dose expansion study of ADI-270 - an Engineered gamma-delta Chimeric Receptor \\[CAR\\] Vδ1 T Cell product Targeting CD70 - in patients with R/R ccRCC."},"conditionsModule":{"conditions":["Clear Cell Renal Cell Carcinoma"],"keywords":["Renal cell carcinoma, cell therapy, CD70, chimeric antigen receptor (CAR) t-cell therapy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SEQUENTIAL","interventionModelDescription":"3+3 Dose Escalation Design","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":60,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Dose Escalation","type":"EXPERIMENTAL","description":"ADI-270 is administered at ascending dose levels as a single dose to determine the maximum tolerated dose (MTD) or maximum assessed dose (MAD) of ADI-270","interventionNames":["Drug: ADI-270","Drug: Fludarabine","Drug: Cyclophosphamide"]},{"label":"Dose Expansion","type":"EXPERIMENTAL","description":"Dose Expansion with ADI-270 at the MTD/MAD to confirm recommended phase 2 dose (Part 2).","interventionNames":["Drug: ADI-270","Drug: Fludarabine","Drug: Cyclophosphamide"]}],"interventions":[{"type":"DRUG","name":"ADI-270","description":"Anti-CD70 CAR-T","armGroupLabels":["Dose Escalation","Dose Expansion"]},{"type":"DRUG","name":"Fludarabine","description":"Chemotherapy for Lymphodepeletion","armGroupLabels":["Dose Escalation","Dose Expansion"]},{"type":"DRUG","name":"Cyclophosphamide","description":"Chemotherapy for Lymphodepletion","armGroupLabels":["Dose Escalation","Dose Expansion"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The Incidence of Subjects with Dose Limiting Toxicities within each dose level cohort","description":"This primary endpoint will be used to determine the Maximum Tolerated Dose (MTD) or Maximum Assessed dose (MAD)","timeFrame":"Day 28"},{"measure":"Proportion of treatment emergent and treatment related adverse events","description":"This primary endpoint will be used to determine the MTD/MAD of ADI-270","timeFrame":"2 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Histologically or cytologically confirmed clear cell RCC\n2. Documented evidence of advanced or metastatic diseases.\n3. Patients must have been treated with an immune checkpoint inhibitor and a VEGF inhibitor (the VEGF inhibitor must have been administered in the advanced and/or metastatic setting).\n4. At least one measurable target lesion according to RECIST 1.1\n5. At least three weeks, or 5 half-lives, whichever is shorter, from the last dose of the prior line of systemic therapy\n6. KPS ≥ 70\n\nExclusion Criteria:\n\n1. Subjects with CNS metastases or spinal cord compression are not eligible, unless they have completed therapy and have discontinued the use of corticosteroids for at least 8 weeks and remained stable prior to enrollment.\n2. Clinically significant CNS dysfunction of any etiology in the opinion of the Investigator.\n3. Prior radiation therapy within 21 days prior to start of study treatment with the exception of palliative radiotherapy to bone lesions (palliative radiotherapy to bone lesions must be completed at least 2 weeks prior to the first dose of LD).\n4. Active malignancy (except for RCC, definitively treated basal or squamous cell carcinoma of the skin, and carcinoma in-situ of the cervix or bladder) within the past 24 months\n5. Treatment with gene therapy, genetically modified cell therapy, or adoptive T cell therapy within 6 weeks before initiating LD in this study.\n6. Receipt of CD70 targeted therapies for any indication\n7. Require corticosteroid therapy \\> 5 mg per day of prednisone or equivalent.\n8. History of any form of primary immunodeficiency such as severe combined immunodeficiency disease.\n9. Presence of active autoimmune disease requiring ongoing systemic immunosuppressive therapy.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Adicet Medical Director","role":"CONTACT","phone":"650-503-9095","email":"clinicaltrials@adicetbio.com"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000002277","term":"Carcinoma"},{"id":"D000002292","term":"Carcinoma, Renal Cell"}],"ancestors":[{"id":"D000009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D000009370","term":"Neoplasms by Histologic Type"},{"id":"D000009369","term":"Neoplasms"},{"id":"D000000230","term":"Adenocarcinoma"},{"id":"D000007680","term":"Kidney Neoplasms"},{"id":"D000014571","term":"Urologic Neoplasms"},{"id":"D000014565","term":"Urogenital Neoplasms"},{"id":"D000009371","term":"Neoplasms by Site"},{"id":"D000052776","term":"Female Urogenital Diseases"},{"id":"D000005261","term":"Female Urogenital Diseases and Pregnancy Complications"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D000007674","term":"Kidney Diseases"},{"id":"D000014570","term":"Urologic Diseases"},{"id":"D000052801","term":"Male Urogenital Diseases"}],"browseLeaves":[{"id":"M5534","name":"Carcinoma","asFound":"Carcinoma","relevance":"HIGH"},{"id":"M5548","name":"Carcinoma, Renal Cell","asFound":"Clear Cell Renal Cell Carcinoma","relevance":"HIGH"},{"id":"M12320","name":"Neoplasms, Glandular and Epithelial","relevance":"LOW"},{"id":"M12315","name":"Neoplasms by Histologic Type","relevance":"LOW"},{"id":"M3585","name":"Adenocarcinoma","relevance":"LOW"},{"id":"M10703","name":"Kidney Neoplasms","relevance":"LOW"},{"id":"M17320","name":"Urologic Neoplasms","relevance":"LOW"},{"id":"M17315","name":"Urogenital Neoplasms","relevance":"LOW"},{"id":"M2875","name":"Urogenital Diseases","relevance":"LOW"},{"id":"M27093","name":"Female Urogenital Diseases","relevance":"LOW"},{"id":"M14127","name":"Pregnancy Complications","relevance":"LOW"},{"id":"M8399","name":"Female Urogenital Diseases and Pregnancy Complications","relevance":"LOW"},{"id":"M10698","name":"Kidney Diseases","relevance":"LOW"},{"id":"M17319","name":"Urologic Diseases","relevance":"LOW"},{"id":"M27095","name":"Male Urogenital Diseases","relevance":"LOW"},{"id":"T4906","name":"Renal Cell Carcinoma","asFound":"Renal Cell Carcinoma","relevance":"HIGH"},{"id":"T1341","name":"Clear Cell Renal Cell Carcinoma","asFound":"Clear Cell Renal Cell Carcinoma","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BXS","name":"Urinary Tract, Sexual Organs, and Pregnancy Conditions"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000003520","term":"Cyclophosphamide"},{"id":"C000024352","term":"Fludarabine"}],"ancestors":[{"id":"D000007166","term":"Immunosuppressive Agents"},{"id":"D000007155","term":"Immunologic Factors"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000018501","term":"Antirheumatic Agents"},{"id":"D000018906","term":"Antineoplastic Agents, Alkylating"},{"id":"D000000477","term":"Alkylating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000970","term":"Antineoplastic Agents"},{"id":"D000019653","term":"Myeloablative Agonists"}],"browseLeaves":[{"id":"M6727","name":"Cyclophosphamide","asFound":"Cycle","relevance":"HIGH"},{"id":"M283230","name":"Fludarabine","asFound":"Comparison","relevance":"HIGH"},{"id":"M225513","name":"Fludarabine phosphate","relevance":"LOW"},{"id":"M10212","name":"Immunosuppressive Agents","relevance":"LOW"},{"id":"M10201","name":"Immunologic Factors","relevance":"LOW"},{"id":"M20604","name":"Antirheumatic Agents","relevance":"LOW"},{"id":"M20942","name":"Antineoplastic Agents, Alkylating","relevance":"LOW"},{"id":"M3820","name":"Alkylating Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"ANeo","name":"Antineoplastic Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}